Lonza expands U.S. manufacturing footprint with Merck KGaA site acquisition
Lonza is expanding its U.S. manufacturing network through a deal to acquire five sites from Merck KGaA. The transaction more than doubles the Swiss contract drug maker's presence in the country and adds capacity in cell and gene therapy.
Highlights
- Lonza will acquire a Merck KGaA U.S. manufacturing site for a low- to mid-triple-digit million Swiss franc sum, closing mid-next year.
- The acquisition expands Lonza's U.S. sites from four to nine and adds around 1,100 employees, deepening capabilities in cell and gene therapy.
- Barclays analysts see strategic upside for Lonza from increased utilization and margin gains, reflecting sector-wide portfolio realignment.
Acquisition terms and portfolio shift
As reported by Reuters, the deal is valued in the low- to mid-triple-digit million Swiss franc range and is expected to close in the middle of next year.Once completed, the acquisition will increase Lonza's number of U.S. sites to nine from four. Around 1,100 employees are set to join Lonza under the transaction, while Merck continues to reshape its business around a more concentrated life science portfolio.
Industry impact and strategic outlook
For Lonza, the added facilities expand its cell and gene therapy capabilities in a market where manufacturing scale and specialized capacity remain important for drug developers. The larger U.S. footprint also strengthens the company's positioning in contract drug manufacturing.Barclays analysts describe the transaction as strategically positive for Lonza, citing potential upside from higher utilisation and margin improvement. The deal also underlines continued portfolio realignment among life sciences groups as companies focus investment on core operations.
Our earlier article on India’s disinvestment programme explained that most proceeds since FY2016 have come from market-based routes such as ETFs, public issues and buybacks, while strategic sales have contributed a relatively small share. It also highlighted how the planned IDBI Bank stake sale stands out against that backdrop and could materially improve the government’s ability to meet its annual disinvestment target once completed.